CALLABLE MULTI DEFENDER VONTI - BRISTOL-MYERS SQUIBB/GILEAD SCIENCES/JOHNSON & JOHNSON/BIOGEN IDEC CALLABLE MULTI DEFENDER VONTI - BRISTOL-MYERS SQUIBB/GILEAD SCIENCES/JOHNSON & JOHNSON/BIOGEN IDEC Share Price
Certificat
RMAS7V
CH1315861554
| Market Closed - Swiss Exchange 16:20:00 28/05/2024 BST | ||
| 99.1 USD | -0.70% |
|
| 1 month | +0.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 28/05/24 | 99.1 | -0.70% |
| 24/05/24 | 99.8 | -0.20% |
| 23/05/24 | 100 | -0.30% |
Delayed Quote Swiss Exchange
Last update May 28, 2024 at 04:20 pm
More quotesStatic data
| Product type | Reverse Convertibles |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| RMAS7V | |
| ISIN | CH1315861554 |
| Date issued | 01/03/2024 |
| Strike | 50.89 $ |
| Maturity | 02/09/2025 (462 Days) |
| Parity | 0.05 : 1 |
| Emission price | 100 $ |
| Emission volume | N/A |
| Settlement | both |
| Currency | USD |
Technical Indicators
| Highest since issue | 101 $ |
|---|---|
| Lowest since issue | 97 $ |
| Spread | 10 $ |
| Spread % | 1.01% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.49
USD
Average target price
53.19
USD
Spread / Average Target
+31.38%
- Stock Market
- Certificates
- RMAS7V Certificat
